ArticleThoracic cancer2026
Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non-Squamous Non-Small Cell Lung Cancer: A Multicenter Retrospective Study.
Article in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Baseline Neutrophil-to-Lymphocyte Ratio and Two-Year Incident Distant Metastasis in Stage I-III Lung Cancer: A Single-Center Retrospective Cohort Study.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
introductionBevacizumab, an anti-VEGF antibody, inhibits angiogenesis and modulates the tumor microenvironment. Because systemic inflammation is linked to VEGF activation and immune modulation, it may affect bevacizumab efficacy. However, this relationship remains unclear. We therefore evaluated whether systemic inflammation, assessed via the serum C-reactive protein (CRP) level, modifies survival benefit when adding bevacizumab to chemoimmunotherapy in advanced non-squamous non-small cell lung cancer (NSCLC).
methodsWe retrospectively analyzed patients with advanced non-squamous NSCLC from 13 Japanese institutions receiving first-line atezolizumab plus chemotherapy with or without bevacizumab between December 2018 and December 2022. The primary endpoint was overall survival (OS). The interaction between CRP level (< 1 mg/dL vs. ≥ 1 mg/dL) and bevacizumab treatment was evaluated, and sensitivity analyses were performed to confirm the robustness of our findings.
resultsAmong 193 eligible patients, 109 (56.5%) received bevacizumab. With a median follow-up of 44.2 months, the median OS was 24.5 months in patients with low CRP and 17.3 months in those with high CRP (log-rank test for trend, p = 0.04). Bevacizumab significantly improved OS in patients with high CRP (hazard ratio [HR] 0.63; 95% confidence interval, 0.40-0.99; p = 0.04), but not in those with low CRP (HR 1.22; p = 0.50). The interaction between CRP level and bevacizumab treatment was significant (p = 0.033). Sensitivity analyses supported these results.
conclusionsSystemic inflammation, as assessed by CRP level, may modify the efficacy of bevacizumab in advanced non-squamous NSCLC. These hypothesis-generating findings warrant prospective validation to clarify the role of CRP in treatment stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.